NDAOPHTHALMICOINTMENT
Approved
May 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LUMI-SPORYN (bacitracin zinc; neomycin sulfate; polymyxin b sulfate) by R-Pharm US. Approved for infection in minor:. First approved in 1971.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUMI-SPORYN is a triple-antibiotic ophthalmic ointment combining bacitracin zinc, neomycin sulfate, and polymyxin B sulfate for topical treatment of minor eye infections. This fixed-dose combination provides broad-spectrum coverage against common bacterial pathogens affecting the eye. It is applied directly to the eye as an ointment for localized anti-infective therapy.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the commercial team is likely in transition planning mode with smaller team sizes focused on retention and deprioritization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on LUMI-SPORYN offers limited career advancement given zero linked job postings and approaching loss of exclusivity. Professionals assigned to this product should view it as a short-term assignment focused on managing decline rather than growth, with emphasis on efficiency and cost optimization.
Brand Manager
Worked on LUMI-SPORYN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.